EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers

Andrew Meci iD, Neerav Goyal, Guy Slonimsky

Cancers · 07.02.2024 · 16 (4) · 703

DOI: 10.3390/cancers16040703 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.02.2024. Verfasst von Andrew Meci und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy is emerging as an effective treatment for advanced head and neck cancers and interest in this treatment modality has led to rapid expansion of this research. Pembrolizumab and nivolumab, monoclonal antibodies directed against the programmed cell death-1 (PD-1) receptor, are US Food and Drug Administration (FDA)- and European Medical Agency (EMA)-approved immunotherapies for head and neck squamous cell carcinoma (HNSCC). Resistance to immunotherapy is common, with about 60% of patients with recurrent or metastatic HNSCC not responding to immunotherapy and only 20–30% of patients without disease progression in the long term. Overcoming resistance to immunotherapy is therefore essential for augmenting the effectiveness of immunotherapy in HNSCC. This review details the innate and adaptive mechanisms by which head and neck cancers can become resistant to immunotherapeutic agents, biomarkers that can be used for immunotherapy patient selection, as well as other factors of the tumor microenvironment correlated with therapeutic response and prognosis. Numerous combinations and novel immunotherapies are currently being trialed, based on better understood immune evasion mechanisms. These potential treatments hold the promise of overcoming resistance to immunotherapy in head and neck cancers.

Schlagwörter

Stichwörter der Autor:innen

HNSCCPD-1 checkpoint inhibitorsimmunotherapyrecurrent and metastatic head and neck squamous cell carcinomaresistance

Autor:innen und Institutionen

  • The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Penn State Health, Milton S. Hershey Medical Center, 500 University Dr, Hershey, PA 17033, USA.

ORCID-Profile: Andrew Meci

Zitieren

APA

Meci, A., Goyal, N., & Slonimsky, G. (2024). Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers. Cancers, 16(4), 703. https://doi.org/10.3390/cancers16040703

Vancouver

Meci A, Goyal N, Slonimsky G. Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers. Cancers. 2024;16(4):703. doi:10.3390/cancers16040703

BibTeX
@article{Meci2024,
  author = {Meci, Andrew and Goyal, Neerav and Slonimsky, Guy},
  title = {Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {703},
  doi = {10.3390/cancers16040703}
}
Kostenlos starten →